Funding for this research was provided by:
Received: 25 January 2022
Accepted: 27 October 2022
First Online: 14 November 2022
: The study was conducted in accordance with the Declaration of Helsinki, and the Ethics Committee of the University Hospitals Essen has approved the study (grant number: 21–10325-BO). All participants signed a digital informed consent prior to study inclusion.
: Not applicable.
: Norbert Scherbaum receives travel grants and honoraria for speaking at or participation in meetings from the following pharmaceutical companies: Camurus, Hexal, MSD, AbbVie, Mundipharma, Indivior and Sanofi-Aventis. Christian Mette has received honoraria from TAKEDA Pharmaceuticals, Germany in 2020. For 2021 the author has nothing to declare. All other authors: declare none.